CREB-Heparan Sulfate-FGF Pathway Inhibition for PTEN-Loss Prostate Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The factors driving the expression of PCa-related genes and their functional consequences in prostate cancer pathogenesis are unclear, necessitating a better understanding to improve treatment strategies for this life-threatening disease.

Innovation Solution

Targeting the CREB-heparan sulfate-FGF pathway by administering inhibitors to treat Pten-loss induced cancer, specifically using CREB inhibitors and heparan sulfate proteoglycan inhibitors to attenuate prostate cancer growth.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatment methods are used, then cancer treatment is provided, but the underlying molecular pathways driving cancer expression remain unclear and treatment effectiveness is limited

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmolecular pathway knowledge

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent identifies CREB as a key intermediary transcription factor that mediates between Pten loss and downstream oncogenic signaling. By targeting CREB specifically, the invention interrupts the molecular pathway without requiring complete knowledge of all intermediate steps, thus improving treatment effectiveness while addressing the information gap through targeted molecular intervention

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the molecular parameter by inhibiting CREB phosphorylation or activity, thereby altering the expression profile of downstream genes. This parameter change approach allows effective treatment by modifying the critical regulatory node (CREB) that controls cancer cell proliferation and survival pathways

Inventive Principle:

Principle #35Parameter changes

2Productivity

If Pten-loss induced cancer is treated without pathway-specific inhibitors, then general cancer treatment is applied, but cancer growth is not effectively attenuated

Engineering Contradiction:

Improvecancer growth rateVSAvoidtreatment efficacy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent segments the cancer treatment approach by specifically targeting the CREB-heparan sulfate-FGF pathway rather than using general cancer treatments. This segmentation allows precise inhibition of the proliferative signaling pathway, effectively reducing cancer growth rate while improving treatment efficacy through pathway-specific intervention

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention extracts and targets the critical CREB-heparan sulfate-FGF signaling axis from the complex cancer cell signaling network. By isolating and inhibiting this specific pathway, the treatment effectively attenuates cancer growth without the side effects and limited efficacy of non-specific cancer treatments

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20260000689A1Targeting CREB-heparan sulfate-FGF pathway for cancer treatment

Publication Date: 2026.01.01 UNIV OF SOUTH FLORIDA

AI summary

The present disclosure provides for a method of treating a Pten-loss induced cancer in a subject in need thereof, the method comprising administering an inhibitor of a CREB-heparan sulfate-FGF axis.